Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
Schmid S, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F, Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, von Moos R, Weder P, Zaman K, Ruhstaller T.
Schmid S, et al. Among authors: von moos r.
BMC Cancer. 2019 Sep 10;19(1):902. doi: 10.1186/s12885-019-6105-3.
BMC Cancer. 2019.
PMID: 31500588
Free PMC article.
Clinical Trial.